Abstract: Compositions and methods are described for the delivery of a fully human post-translaionally modified (HuPTM) monoclonal antibody (“mAh”) or the antigen-binding fragment of a mAh against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with diabetic retinopathy.

Abstract: Compositions and methods are described for the delivery of therapeutic products (such as therapeutic proteins (for example, antibodies), therapeutic RNAs (for example, shRNAs, siRNAs, and miRNAs), and therapeutic aptamers) to the retina/vitreal humour in the eyes of human subjects to treat pathologies of the eye, involving, for example, recombinant viral vectors such as recombinant adeno-associated virus (rAAV) vectors.

Abstract: The present disclosure relates to systems and methods for lending transactions. A system for lending transactions includes at least one memory storing instructions, and at least one processor configured to execute the instructions to perform operations. The operations include receiving a transaction posted to an account of an existing customer having a credit score above a threshold required by the credit service provider, a customer account associated with the existing customer having a credit limit; receiving an indication from the existing customer that the received transaction is associated with a purchase made by a non-customer; generating a transaction account having a balance associated with the transaction without verifying a credit score of the non-customer; receiving and tracking payments made by the non-customer for the transaction account; and closing the transaction account when payment of the transaction balance is complete.